Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity

被引：33

作者：

Moon, C ^{[1
]}

Verschraegen, CF ^{[1
]}

Bevers, M ^{[1
]}

Freedman, R ^{[1
]}

Kudelka, AP ^{[1
]}

Kavanagh, JJ ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Internal Med Specialities, Sect Gynecol & Med Therapeut, Houston, TX 77030 USA

来源：

ANTI-CANCER DRUGS | 2000年 / 11卷 / 07期

关键词：

allergic reactions; ovarian neoplasms; taxane;

D O I：

10.1097/00001813-200008000-00007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaphylaxis or significant hypersensitivity reaction is one of the most catastrophic potential complications of chemotherapy. There is a 2-5% risk of hypersensitivity with paclitaxel, a commonly used chemotherapeutic agent for various cancers. Three patients, who developed hypersensitivity to paclitaxel infusion, received docetaxel without allergic reactions. Docetaxel may therefore be an alternative treatment for patients with paclitaxel hypersensitivity. [(C) 2000 Lippincott Williams & Wilkins].

引用

页码：565 / 568

页数：4

共 15 条

[1] Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions [J].